Literature DB >> 6180056

Augmentation of human natural killer cell activity by interferon: conditions required for boosting and characteristics of the effector cells.

J R Ortaldo, N P Lang, T Timonen, R B Herberman.   

Abstract

Human effector cells of natural killer (NK) activity have been augmented by pretreatment with a partially purified preparation of interferon (IFN-beta). Using the 4-hr 51Cr release assay to measure cytotoxicity, the boosted effector cells, as well as the spontaneous NK cells, were nonphagocytic cells with receptors for the Fc portion of IgG. Augmentation of cytolytic activity occurred: (1) in medium with either fetal calf serum and human serum; (2) in the presence of absence of monocytes; (3) in both sheep RBC rosette-forming and non-rosette-forming populations; and (4) when only the effector cells were pretreated with interferon. This last observation led to the finding that less than or equal to 5 min of contact at 37 degrees C, 22 degrees C, or 4 degrees C with interferon was necessary for augmentation of cytotoxicity. Augmentation kinetics demonstrated significant boosting of NK activity in peripheral blood leukocytes and highly NK-enriched Percoll fractions after 1 hr of contact with IFN-beta or pure IFN-alpha-Collectively, these results indicate that NK boosting with interferon: (1) occurs after a rapid temperature-independent binding to the effector cells; and (2) has a rapid effect on the cytolytic process.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6180056     DOI: 10.1089/jir.1981.1.253

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  4 in total

1.  Phenotypes and spontaneous cell cytotoxicity of mononuclear cells from patients with seronegative spondyloarthropathies: ankylosing spondylitis, psoriatic arthropathy and pauciarticular juvenile chronic arthritis--analysis of mononuclear cells from peripheral blood, synovial fluid and synovial membranes.

Authors:  J Thoen; O Førre; K Waalen; J Pahle
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

2.  Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36.

Authors:  J M Pelham; J D Gray; G R Flannery; M V Pimm; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

3.  Impaired interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum.

Authors:  A A Gaspari; T A Fleisher; K H Kraemer
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

4.  Natural killer (NK) cells at inflammatory sites of patients with rheumatoid arthritis and IgM rheumatoid factor positive polyarticular juvenile rheumatoid arthritis.

Authors:  J Thoen; K Waalen; O Førre
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.